

# 1 Human placental villi immune cells help maintain homeostasis *in utero*

2  
3 Jessica M Toothaker<sup>1,2</sup>, Oluwabunmi Olaloye<sup>2</sup>, Blake T. McCourt<sup>2</sup>, Collin C McCourt<sup>5</sup>, Rebecca  
4 M Case<sup>5</sup>, Peng Liu<sup>6</sup>, Dean Yimlamai<sup>2</sup>, George Tseng<sup>6</sup>, Liza Konnikova<sup>2-4\*</sup>

5  
6 <sup>1</sup>Department of Immunology, University of Pittsburgh, PA, USA

7 <sup>2</sup>Department of Pediatrics, <sup>3</sup>Reproductive Sciences, <sup>4</sup>Program in Human Translational  
8 Immunology, Yale University, New Haven, CT, USA

9 <sup>5</sup>Department of Pediatrics, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, USA

10 <sup>6</sup>Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA

11  
12 \*To whom correspondence should be addressed: Liza Konnikova [liza.konnikova@yale.edu](mailto:liza.konnikova@yale.edu)

## 13 **Abstract**

14 Maintenance of healthy pregnancy is reliant on successful balance between the fetal and  
15 maternal immune systems. Although maternal mechanisms responsible have been well studied,  
16 those used by the fetal immune system remain poorly understood. Using suspension mass  
17 cytometry and various imaging modalities, we report a complex immune system within the mid-  
18 gestation (17-23 weeks) human placental villi (PV). Further, we identified immunosuppressive  
19 signatures in innate immune cells and antigen presenting cells that potentially maintain immune  
20 homeostasis in utero. Consistent with recent reports in other fetal organs, T cells with memory  
21 phenotypes were detected within the PV tissue and vasculature. Moreover, we determined PV T  
22 cells could be activated to upregulate CD69 and proliferate after T cell receptor (TCR)  
23 stimulation and when exposed to maternal uterine antigens. Finally, we report that cytokine  
24 production by PV T cells is sensitive to TCR stimulation and varies between mid-gestation,  
25 preterm (26-35 weeks) and term deliveries (37-40 weeks). Collectively, we elucidated the  
26 complexity and functional maturity of fetal immune cells within the PV and highlighted their  
27 immunosuppressive potential.

## 28 29 **Introduction**


30 Successful pregnancy is dependent on a delicate immune homeostasis, yet many of the  
31 factors required to maintain this homeostasis remain elusive. It is understood that the maternal  
32 immune system must balance pathogen defense while also preventing rejection of the semi-  
33 allogenic fetus for ~40 weeks in a healthy full term pregnancy (Erlebacher, 2013; PrabhuDas et  
34 al., 2015). Adding to the complexity, the progression of pregnancy is mirrored by distinct  
35 physiological states at many sites throughout the body requiring the maternal immune system to  
36 be equally dynamic and adaptive. This point is clearly illustrated in the seminal study by  
37 Agheepour and colleagues that tracked immunological responses in the periphery from early  
38 gestation through delivery using mass cytometry (CyTOF) (Aghaeepour et al., 2017). Many  
39 studies have identified numerous mechanisms by which the maternal immune system

40 accommodates the developing fetus at the fetal-maternal interface. These include: the detection  
41 of suppressive uterine NK cells reviewed in (Gaynor and Colucci, 2017), presence of novel T  
42 regulatory (Treg) populations (Salvany-Celades et al., 2019), detection of suppressive B cells  
43 (Huang et al., 2017), restricted access to plasmacytoid dendritic cells (pDC) (Li et al., 2018) and  
44 a predominance of type 2 helper T cells (Miyazaki et al., 2003). The importance of the maternal  
45 immune system in pregnancy cannot be understated, however recent findings suggest that the  
46 fetal immune system must also be considered to fully understand placental immune  
47 homeostasis throughout gestation.

48 Historically, the fetal and neonatal immune systems were thought to be immature. This  
49 hypothesis was supported by poor vaccine responses in neonates (Saso and Kampmann,  
50 2017), high susceptibility to infection (Simonsen et al., 2014), and the predominance of naïve  
51 lymphocytes in human cord blood (Palocz, 1999). However, novel insights suggest that the fetal  
52 and neonatal immune systems are developed, though potentially have altered functions. Work  
53 supporting this concept includes: the *in utero* maturation following education of fetal Tregs (Mold  
54 et al., 2008), detection of novel immunosuppressive cell types present in neonatal blood (Elahi  
55 et al., 2013; Halkias et al., 2019; Miller et al., 2018a), and the presence of *in utero* memory  
56 lymphocytes in many fetal tissues (Li et al., 2019; Odorizzi et al., 2018; Schreurs et al., 2019;  
57 Stras et al., 2019a; Zhang et al., 2014). However, our knowledge about the immunological  
58 capabilities of the fetal cells at the fetal maternal interface is sparse.

59 A collection of recent single cell RNA-sequencing studies of the first trimester fetal-  
60 maternal interface revealed multiple previously undocumented PV cell types and cell-cell  
61 interactions (Suryawanshi et al., 2018; Vento-Tormo et al., 2018). Similarly, detection of novel  
62 cell populations and interactions was observed in third trimester placental surveys (Pavličev et  
63 al., 2017; Pique-Regi et al., 2019). Of interest, the work by Pique-Regi specifically identified PV-  
64 specific immune cell signatures, notably the presence of both resting and activated T cells of  
65 fetal origin in term PV (Pique-Regi et al., 2019). These data are in line with other work detecting  
66 a previously undocumented complex and diverse PV immune system in third trimester preterm  
67 rhesus macaques, which also contained T cells with activated phenotypes (Toothaker et al.,  
68 2020).

69 Building on these studies we hypothesized that the active PV immune system detected  
70 in the third trimester (Pique-Regi et al., 2019; Toothaker et al., 2020) must be present and  
71 contribute to immune homeostasis at mid-gestation. Using a combination of RNA-sequencing,  
72 CyTOF, imaging mass cytometry (IMC), and florescent microscopy, we investigated the PV  
73 immune profile from healthy mid-gestation (17-23 weeks) placental tissues. With this unique  
74 sample cohort, we detected multiple PV-specific immune signatures (absent in the decidua and  
75 membranes from the chorionic plate). We also identify that PD-L1 expression on antigen  
76 presenting cells is reduced in preterm placentas suggesting that PD-L1 expression may help  
77 keeps this armed PV immune system homeostatic *in utero*. Furthermore, using functional  
78 assays we uncovered that the PV T cells are poised to execute mature inflammatory functions  
79 as early as 18 weeks' gestation, and that the cytokine secretion of PV T cells is variable in mid-  
80 gestation and preterm pregnancies but consistent across term pregnancies after T cell receptor  
81 (TCR) stimulation.




82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93

**Figure 1. Tissue specific signatures in the mid-gestation placenta.** (A) Diagram of placental tissues. (B) Representative H&E staining of layers of placental tissues. (C) All differentially expressed genes between three placental tissues with p value <0.05, false-discovery rate <20%, and fold change > absolute value 2. (D) Representative image of CD45<sup>pos</sup> CD163<sup>lo/h</sup>eg cells within the intravillous space identified with immunofluorescence. (E) Representative image for fluorescent *in situ* hybridization of Y chromosome in PV (top). Delta CT values of Y and X chromosome genes in male and female PV (bottom). (F) Expression values of selected immune genes. Circle size indicative of expression value. Circle color indicative of relative expression across row. \* = p value <0.05 upon post hoc analysis after Kruskal-Wallis (K-W) test. DE = differentially expressed. CP= chorionic plate.

## 94 Results

### 95 96 *The human mid-gestation PV have tissue specific immune signatures*

97  
98 We collected placental specimens from 19 second trimester products of conception,  
99 gestational age (GA) 17-23 weeks (**Table S1**). Maternal decidua and fetal chorionic/amniotic  
100 membranes covering the chorionic plate (referred to hereafter as CP) were separated from the  
101 PV (**Fig 1A**) with forceps under a dissecting microscope. Separation of layers was initially  
102 confirmed by histology (**Fig 1B**). Tissue was then either cryopreserved for CyTOF analysis, as  
103 previously described (Konnikova et al., 2018; Stras et al., 2019a) and validated in **Fig S1A**,  
104 fixed with formalin prior to embedding in paraffin for imaging mass cytometry (IMC) and  
105 immunofluorescence (IF) analysis or snap frozen for bulk RNA-sequencing (RNAseq). To verify  
106 separation of placental layers, we used bulk RNAseq from 3 matched cases (**Table S1**).  
107 Differential expression analysis (**Table S2**) and hierarchical clustering confirmed segregation of  
108 layers based on transcription profiles with the exception of one outlier (CP3) sample which was  
109 enriched for inflammatory signatures, likely upregulated during the D&E procedure or secondary  
110 to undocumented *in utero* inflammation (**Fig 1C**). This segregation of samples was confirmed  
111 with k-means clustering which grouped samples correctly by tissue with the exception of CP3  
112 outlier (**Fig 1C**). Moreover, we confirmed the enrichment of decidua and PV specific stromal  
113 genes previously reported in multiple studies (Pique-Regi et al., 2019; Suryawanshi et al., 2018;  
114 Vento-Tormo et al., 2018) and detected two tubulin genes, TUPP3 and TUBAL3 enriched in all  
115 three CP samples. To determine if immune cells in the mid-gestation PV were solely reflective  
116 of the Hofbauer cell population we used immunofluorescence to co-stain for CD45, a marker of  
117 all hematopoietic cells and CD163, a classical PV resident Hofbauer cell marker (Reyes and  
118 Golos, 2018). Consistent with previous reports identifying non-Hofbauer immune subsets in the  
119 first and third trimester PV (Bonney et al., 2000; Pique-Regi et al., 2019), we detected  
120 CD45<sup>pos</sup>CD163<sup>lo</sup> cells within the mid-gestation PV (**Fig 1D**) ranging in abundance from 30-70%  
121 of CD45<sup>pos</sup> nuclei per high power field (**Fig S1B**). As the PV are bathed in maternal blood  
122 (intervillous), we also confirmed that immune cells present in PV samples were reflective of cells  
123 contained within the trophoblast layers PV itself (intravillous) and not simply contamination from  
124 maternal blood cells (**Fig 1D, S1B**). Additionally, we detected the Y chromosome with *in situ*  
125 hybridization in many intravillous cells and had enriched expression of Y chromosome derived  
126 *EIF1AY* mRNA coupled with low expression of the X chromosome inactivation transcript *XIST* in  
127 male PV samples indicating that the majority PV immune cells in our study were fetal in origin  
128 (**Fig 1E, S1C**). To gain insight into what the CD45<sup>pos</sup>CD163<sup>lo/neg</sup> immune cell subsets could be,  
129 we next assessed the expression of immune genes in our RNAseq dataset and confirmed the  
130 presence of a diverse immune landscape in mid-gestation placental tissues. Though most  
131 transcripts in the PV were expressed at lower levels than decidual counterparts (darker in color),  
132 transcripts for most major immune subtypes analyzed were detected in PV samples (circle size)  
133 including T cells, B cells, DCs and macrophages (Mφs) (**Fig 1F, Table S3**).




**Figure S1.** (A) Comparison of CyTOF analysis of CD45<sup>pos</sup> and T cell abundances between fresh PV, cryopreserved PV and frozen Peripheral Blood Mononuclear Cells (PBMCs). (B) Splits of immunofluorescence for intravillous immune cell detection and quantification of CD163<sup>hi</sup> immune cells. (C) Splits for Y-chromosome *in situ* hybridization.

To survey the CD45<sup>pos</sup> populations in the PV, we used a panel of 38 metal conjugated antibodies (**Table S4**) and performed CyTOF analysis on 12 placenta-matched decidua, CP and PV samples (**Table S1**). Briefly, cryopreserved tissues were then batch thawed and digested to make single cell suspensions, stained with metal conjugated antibodies (**Table S4**) and analyzed using CyTOF (Konnikova et al., 2018) (**Fig S1A**). FCS files from CyTOF analysis were pre-gated for DNA<sup>pos</sup>, single, live, non-bead, CD45<sup>pos</sup> cells (**Fig S2A**). After omitting samples with insufficient cell numbers (>750 CD45<sup>pos</sup> cells) we were left with 11 total samples for each tissue layer (**Table S5**). CD45<sup>pos</sup> cells were clustered using an automated clustering algorithm, Phenograph (**Fig 2A**) and clusters identified based on mean metal intensities of the surface markers from Clustergrammer generated associated heatmaps (**Table S6, Fig S2B**).

To confirm that PV immune subsets identified were not solely reflective of blood leukocytes in the fetal circulation, we used immunofluorescence (IF) and imaging mass cytometry (IMC) with a panel that included 23 markers (**Table S7**) on 6 total regions of 2 individual PV cases (**Table S1**). Using IMC, we validated that B cells, DCs, T cells and Mφs were found outside the fetal vasculature (CD31) in the PV stroma (**Fig 2B-F**). Due to technical limitations in generating IMC antibodies to identify NK cells and ILCs, we used dual *in situ* hybridization and immunofluorescence to detect these populations in the PV as well (**Fig 2C,G**). Though it is likely that some PV immune cells detected with CyTOF represent blood leukocytes, we can conclude that a proportion of the PV immune cells represent stromal populations.

To further characterize these cells, we used CyTOF analysis consisting of 31 unique clusters of immune cells within the STP, belonging to Mφ, DC, NK, CD4 T cell, CD8 T cell, double positive (DP) T cell, B cell and other immune cell type subsets (**Fig 2H, S2B**). Each layer of the placenta housed a unique and complex immune profile (**Fig S2C**). When all clusters belonging to the same immune subset were combined, the decidua had a greater abundance of NK cells compared to PV (**Fig 2H**), consistent with previous studies (King et al., 1991; Koopman et al., 2003). Additionally, there was a higher proportion of CD4 T cells in the decidua than either of the fetal layers, likely attributed to the documented high abundance of decidual Tregs (**Fig 1H**). In contrast, the PV had a larger proportion of Mφ than either the decidua or CP, potentially representing the Hofbauer population (**Fig 2H**).




169  
170  
171  
172

**Figure 2. Global Immune Landscape of Second Trimester Placenta.** (A) Merged tSNE of CD45<sup>pos</sup> cells from maternal decidua (n=11), CP (n=11) and PV (n=11) from Phenograph clustering of CyTOF data. (B) IMC identifying B cells (green) arrows located within the trophoblast bound (red) and outside the fetal

173 blood vessels (BV) (white arrows). (C) Dual in situ hybridization and immunofluorescence (IF) identifying  
174 NK cells (green arrow) phenotypically distinct from T cell (yellow arrowhead) in PV. (D) IMC identifying  
175 DCs (pink arrows) and HLA-DR<sup>pos</sup> Mφs (green arrows). (E) IMC identifying T cells (green arrows). (F) IMC  
176 identifying Mφs (green arrows). (G) Dual in situ hybridization and IF identifying ILC2s (green arrow)  
177 phenotypically distinct from T cell (yellow arrowhead) in PV. (H) Stacked bar graph comparing summation  
178 of all clusters belonging to same immune subsets from CyTOF data. (I) Density plot reflective of  
179 populations in (A) segregated by tissue of origin. Clusters significantly enriched in PV outlined. (J)  
180 Quantification of PV enriched cluster abundance. K-W = Kruskal-wallis test. \* = p value <0.05 following  
181 posthoc analysis.

182 When each cluster abundance was directly compared, 11/31 CD45<sup>pos</sup> clusters were  
183 differently distributed between the three layers of the placenta (**Fig 2I-J, S2D**). The PV was  
184 uniquely enriched for cluster 19 CCR7<sup>neg</sup> Mφs (**Fig 1I-J**). This robust cluster similarly suggests  
185 the presence of Hofbauer cells (as prior reports show most Hofbauer cells are CCR7<sup>neg</sup> (Joerink  
186 et al., 2011) ) in the PV and confirms the tissue-specificity of Hofbauer cells in our data set due  
187 to this cluster being largely undetectable in decidua and CP samples (**Fig 2J**). Interestingly, we  
188 also found cluster 10, CCR7<sup>neg</sup> DCs, and cluster 3, CD69<sup>neg</sup> CD8 T cells, to be enriched in the  
189 PV over decidua (**Fig 2I-J**). CCR7 is highly expressed on DCs homing to secondary lymphoid  
190 structures from peripheral tissues after antigen encounter (Ohl et al., 2004). CD69 is found to be  
191 transiently upregulated on activated T cells (Cibrián and Sánchez-Madrid, 2017) and  
192 constitutively upregulated on tissue resident memory T cells (Kumar et al., 2017). As PV  
193 enriched clusters 9 and 3 lacked these respective markers, we hypothesize that PV are poised  
194 (immune cell types are present) to execute mature immune function, such as antigen  
195 presentation, but may not be actively performing such functions during a time of homeostasis  
196 such as mid-gestation in healthy pregnancies. To further explore this idea, we next analyzed  
197 each immune cell subset more thoroughly.



198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208

**Figure S2.** (A) Pre-gating strategy for CD45<sup>pos</sup> population used in automated clustering. (B) Clustergrammar heatmap used for cluster identification (left) of tsne clusters mapped (right). (C) Linkage Disequilibrium (LD) plot confirming segregation of placental layer immune profile. (D) Abundance of decidua and CP enriched clusters. \* = p value < 0.05 after posthoc analysis from Kruskal-Wallis (K-W) test.




209 *PV innate cells have quiescent phenotypes*

210

211 To evaluate PV non-antigen presenting innate cell subsets independent of their antigen  
212 presentation abilities that represent the first cells to sense foreign antigens, we clustered on  
213 CD3<sup>neg</sup>CD19<sup>neg</sup>HLA-DR<sup>neg</sup> cells (**Fig S3A**). We identified Mφs, innate lymphoid cells (ILCs), NK  
214 cells and multiple other immune cell populations that we were unable to fully phenotype with our  
215 panel (**Table S4**), (**Fig 3A, S3B**). When comparing subtypes of immune cells, i.e. individual  
216 clusters of the same subtype added together, we confirmed our findings from the CD45 level  
217 (**Fig 1H**), with the decidua having a larger proportion of NK cells and the PV having a larger  
218 proportion of Mφs (**Fig 2B**). The increased granularity of focusing on HLA-DR<sup>neg</sup> innate cells  
219 specifically, revealed that Mφs were both CD163<sup>hi</sup> likely representing the Hofbauer cell  
220 population, and also contained a significant proportion CD163<sup>lo</sup> Mφs, presumably other non-  
221 Hofbauer cell Mφs (**Fig 3B**). HLA-DR<sup>neg</sup> Mφs in the decidua, in contrast were largely CD163<sup>hi</sup>,  
222 consistent with previous data on the phenotype of decidual Mφs (Jiang and Wang, 2020) and  
223 with the enriched CD163 gene signatures seen in the decidua over CP from RNAseq data (**Fig**  
224 **1D**). The Mφ profile in the CP was more equally split between the two CD163<sup>lo</sup>phenotypes (**Fig**  
225 **3B**). At the individual cluster level, multiple clusters were enriched in either the decidua and/or  
226 CP (**Fig S3C**). Within the PV there were enriched in cluster 25, CD163<sup>lo</sup> Mφs, and cluster 27, NK  
227 cells (**Fig 3C**). While cluster 27 NK cells were abundant in all three placental layers and only  
228 slightly elevated in the PV, cluster 25 Mφs were specific to the PV and were only minimally  
229 present in decidua and CP (**Fig 3C**).


230 To determine if PV NK and ILCs were expressing markers consistent with activation, we  
231 compared the mean metal intensities (MMIs) of CD69 and PD-1 on these cells and found that  
232 PV NK cells and ILCs expressed significantly lower amounts of both CD69 and PD-1 than  
233 decidual and CP counterparts (**Fig 3D**). Next, to examine if PV innate cells have migratory or  
234 tissue-retentive phenotypes we compared chemokine receptor (CCR) expression among  
235 subsets. Illustrated both visually (**Fig 3E**) and graphically (**Fig 3F**) we show that multiple  
236 populations of PV innate cells including NK cells, ILC and CD163<sup>hi</sup> Mφs had reduced expression  
237 of four CCRs. Interestingly, the expression of these markers between the three compartments  
238 was similar for the CD163<sup>lo</sup> Mφs (**Fig 3F**). To determine if other chemokine receptor/ligand pairs  
239 were also reduced in the PV, we identified 19 chemokine receptors/ligands that were  
240 differentially expressed between PV, CP and decidua using bulk RNA-seq (**Fig 3G, Table S8**).  
241 These results validated the CyTOF findings of reduced expression of CCR6 and CXCR3  
242 specifically, as well as at least one ligand for CCR7 and CCR4. Nine other chemokine  
243 ligand/receptors were implicated in this dataset (**Fig 3G**). These results suggest that PV innate  
244 cells are either static or are migrating in a non-signal specific manner and in combination with  
245 low expression of activation marker on PV immune cells, support a quiescent state of PV innate  
246 cells at mid-gestation.



247  
 248  
 249  
 250  
 251  
 252

**Figure 3. Innate HLA-DR<sup>neg</sup> cells in PV.** (A) Combined CyTOF t-sne for CD45<sup>pos</sup> CD3<sup>neg</sup> CD19<sup>neg</sup> HLA-DR<sup>neg</sup> cells. (B) Stacked bar graph of abundance of major immune subtype. (C) Density plots separated by tissue of cell populations from (A). Statistically significantly abundant clusters in PV outlined. (right side) Cumulative data of PV abundant clusters outlined in density plots. (D) Mean metal intensities(MMI) of CD69 (top) and PD-1 (bottom) for 2D gated NK and ILC populations. (E) Expression heatmaps for

253 chemokine receptors mapped to cells identified in (A). (F) MMLs of chemokine receptors on innate cell  
 254 subsets from 2D gating. (G) Expression from RNA-sequencing of differentially expressed chemokine  
 255 ligand/receptor genes between tissues. Circle size indicative of expression value, circle color reflective of  
 256 relative expression across row. Differentially expressed determined as: p value <0.05, false-discovery  
 257 rate <20%, and fold change > absolute value 2. \* = p value <0.05 upon post hoc analysis after Kruskal-  
 258 Wallis(K-W) test. DE= differentially expressed.



260  
 261 **Figure S3.** (A) Pregating strategy for innate non-APC population. (B) Clustergram heatmap  
 262 used for cluster identification (left) of tsne clusters mapped (right). (C) Cumulative data on  
 263 abundance of decidua and CP enriched clusters. \* = p value < 0.05 after posthoc analysis from  
 264 Kruskal-Wallis (K-W) test.

265  
 266  
 267 *PV antigen presenting cells are diverse and phenotypically immunosuppressive*


268  
 269 Next, we examined APC populations within each placental layer by clustering on  
 270 CD45<sup>pos</sup> CD3<sup>neg</sup> HLA-DR<sup>pos</sup> cells (**Fig S4A**). We identified seven sub-types of APCs including:  
 271 myeloid DCs (mDCs), plasmacytoid DCs (pDCs), CD163<sup>hi</sup> Mφs, CD163<sup>lo</sup> Mφs, B cells, NK cells  
 272 and other cell types that we could not identify based on the available markers (**Fig 4A, S4B**). In  
 273 confirmation of our previous findings (**Fig 2-3**), NK cells were again more prevalent in the  
 274 decidua compared to the PV (**Fig 4B**). HLA-DR<sup>pos</sup> NK cells that are capable to independently  
 275 present antigens to CD4 T cells have been described (Roncarolo et al., 1991). In contrast to

276 HLA-DR<sup>neg</sup> innate cells (**Fig 3**), numerous individual APC clusters were enriched in the PV (**Fig**  
277 **4C**). Of note, multiple populations were enriched in the decidua and CP as well (**Fig S4C**).  
278 Specifically, B cell clusters 7 and 27, mDC clusters 16 and 20, and CD163<sup>lo</sup> CD4<sup>neg</sup> M $\phi$  clusters  
279 6 and 22 were significantly more abundant in the PV than either decidua or CP (**Fig 4C**).  
280 Complimenting this finding, CD4<sup>pos</sup> CD163<sup>hi</sup> M $\phi$ s (cluster 26) was reduced in the PV compared to  
281 decidua and CP (**Fig S4C**). CD4<sup>pos</sup> M $\phi$ s have been shown to be long lived tissue resident M $\phi$ s in  
282 the intestine and perhaps they serve a similar role in the decidua (Shaw et al., 2018). The large  
283 number of APC clusters (11 in total) differentially abundant between the PV and decidua/CP  
284 suggests that antigen presentation in the PV may be functioning through non-classical  
285 mechanisms at mid-gestation.

286 To investigate potential functional distinctions in PV APCs, we examined the expression  
287 of both activation and immunosuppressive markers on each APC subset identified in **Figure 4B**.  
288 In contrast to the hypothesis that PV APCs have altered ability to function as APCs compared to  
289 decidua and CP, we found no difference in HLA-DR expression among APC subsets (**Fig 4D**).  
290 However, consistent with PV APCs being more inhibited than decidua and CP counterparts, we  
291 identified significantly reduced expression of the activation maker CD69 in the PV CD163<sup>hi</sup> M $\phi$ s,  
292 NK cells, pDCs and mDCs (**Fig 4E**). Furthermore, when we examined the inhibitory ligand, PD-  
293 L1, we documented its increased expression on multiple APC subsets, significantly so on  
294 CD163<sup>lo</sup> M $\phi$ s and HLA-DR<sup>pos</sup> NK cells (**Fig 4F**). This observation of high PD-L1 expression on  
295 PV APCs was confirmed by IF staining, where almost every observable PV HLA-DR<sup>pos</sup> cell co-  
296 expressed PD-L1 (**Fig 4G, S4D**).


297 To determine if PD-L1 expression on PV APCs is important for maintaining healthy  
298 pregnancy we compared both PD-L1 and HLA-DR expression in the PV stroma with  
299 immunohistochemistry (IHC) between healthy mid-gestation placentas (21-23 weeks' gestation),  
300 preterm placentas from complicated pregnancies (29-35 weeks' gestation) and healthy  
301 placentas delivered at full-term (39 weeks' gestation) (**Fig 4H**). Consistent with our CyTOF  
302 findings, mid-gestation stromal cells have high expression of PD-L1 per nuclei and PD-L1  
303 staining patterns are congruent with stromal HLA-DR staining indicating that the PD-L1<sup>pos</sup> cells  
304 analyzed were likely APCs (**Fig 4H**). Of note, we discovered that stromal PD-L1 expression in  
305 preterm PV is significantly lower than that of mid-gestation and term PV. Furthermore, term PV  
306 also have significantly reduced PD-L1 expression on stromal cells than mid-gestation PV (**Fig**  
307 **4H**). In contrast, we observed increased PD-L1 expression on preterm trophoblasts compared  
308 to mid-gestation trophoblasts (**Fig S4E**). To confirm that the reduction of stromal PD-L1 was not  
309 an artifact of reduced APC abundance in preterm and term placentas we compared mean HLA-  
310 DR expression between all three groups and found no differences (**Fig 4H**). These results  
311 suggest PD-L1 expression on PV APCs helps maintain homeostasis during pregnancy  
312 illustrated by the highest expression during the mid-gestation window and significantly reduced  
313 expression in complicated (preterm) pregnancies.

314 To investigate the regulation of constitutive PD-L1 expression by PV APCs we measured  
315 the expression of IFN $\gamma$ , a well-documented regulator of PD-L1 (Garcia-Diaz et al., 2017). We  
316 hypothesized constitutive expression of PD-L1 on PV APCs may be resultant from IFN $\gamma$  (a  
317 regulator of PD-L1) production. Consistent with this hypothesis we found preferential  
318 transcription of IFN $\gamma$  over TNF $\alpha$  at baseline by PV immune cells (**Fig 4I, S4F**). Additionally, PV  
319 immune cells transcribe comparable IFN $\gamma$ , but transcribe decreased TNF $\alpha$  than decidual  
320 immune cells (**Fig S4G**). The preferential production of IFN $\gamma$  to TNF $\alpha$  was confirmed in PV  
321 immune cells with flow cytometry. We report this IFN $\gamma$  was mostly derived from non-NK cell  
322 innate immune cells (**Fig 4J**). As such, it is possible that PV immune cells produce IFN $\gamma$  during  
323 homeostasis to drive expression of PD-L1 on APCs.



324  
 325 **Figure 4. Antigen Presenting Cells in the PV.** (A) Cumulative CyTOF tSNE for CD45<sup>pos</sup> CD3<sup>neg</sup> HLA-  
 326 DR<sup>pos</sup> cells. (B) Stacked bar graph of abundance of major immune subtype. (C) Density plot separated by  
 327 tissue of origin from (A). Statistically significantly abundant clusters in PV outlined. Cumulative data of PV  
 328 abundant clusters outlined in density plots. MMI of HLA-DR (D), CD69 (E) and PD-L1 (F) for 2D gated  
 329 populations. \* = p value < 0.05 upon post hoc analysis after Kruskal-Wallis test. (G) Representative image  
 330 of PD-L1<sup>pos</sup> APC populations in PV. (H) Representative images (left) and quantification of average stain  
 331 intensity per stromal nuclei (right) for PD-L1 and HLA-DR IHC. (I) Representative images (left) and

332 quantification of automated image analysis with CellProfiler (right) for dual RNA *in situ* hybridization and  
 333 immunofluorescence in PV. (J) Representative flow plots and quantification for cytokine positive PV  
 334 immune cells via flow cytometry. Pie-chart representing major immune subset abundance of IFN $\gamma$ <sup>pos</sup>  
 335 immune cells from flow cytometry. \* = p-value <0.05 in Mann-Whitney two-tailed test. K-W = Kruskal  
 336 Wallis test p value. MMI = mean metal intensity.  
 337



338 **Figure S4.** (A) Pregating strategy for APC population. (B) Clustergram used for cluster  
 339 identification (left) of tSNE clusters mapped (right). (C) Cumulative data on abundance of decidua and CP  
 340 enriched clusters. \* = p value < 0.05 after posthoc analysis from Kruskal-Wallis (K-W) test. (D) Splits for  
 341 PD-L1<sup>pos</sup> PV APCs representative image. (E) Quantification of trophoblast expression of PD-L1 via IHC.  
 342 (F) Splits for dual RNA *in situ* hybridization and IF. Representative images in main figure taken from  
 343 region identified in white rectangle. (F) Quantification of staining for cytokine positive immune cells in PV  
 344 and decidua. (H) Pregating for CD45<sup>pos</sup> population with flow cytometry. \*\*\* = p-value < 0.001 in Mann-  
 345 Whitney two tailed test.  
 346  
 347

348 *The second trimester placenta is dominated by memory CD8 T cells*


349 As we observed high PD-L1 expression on APCs, we next explored if there were T cells  
350 present in the PV that would be inhibited by immunosuppressive APCs. We identified both  
351 circulating (within blood vessel) and potentially tissue resident T cells in the PV (**Fig 5A, S5A**).  
352 Moreover, using IMC, we surprisingly identified non-circulating T cells of CD4, CD8 and double  
353 negative (DN) phenotypes that expressed CD45RO, a marker upregulated after antigen  
354 experience and absent on naïve T cells (**Fig 5B, S5B**). Turning to our CyTOF data, when  
355 clustering specifically on T cells (**Fig S5C**), we found that all three layers of the placenta had a T  
356 cell profiles dominated by CD8 T Cells (**Fig 5C-D, S5D**). Building off the initial detection of  
357 CD45RO by IMC, we found that the majority of T cells in the PV were of memory phenotypes,  
358 delineated based on expression of CCR7 and CD45RA (**Fig 5E**). Additionally, we found CD8 T  
359 cells with tissue-resident memory (TRM) phenotype in all three layers (**Fig 5E**). We detected  
360 CD69<sup>pos</sup> T cells both as a marker of TRMs on CCR7<sup>neg</sup> CD45RA<sup>neg</sup> T cells and also among other  
361 T cell subsets (**Fig 5E**). The expression of CD69 on multiple T cell populations strongly  
362 suggests that some populations of PV T cells are stromal and not reflective of fetal blood T  
363 cells, because recent work has shown that blood CD8 T cells do not express CD69 (Buggert et  
364 al., 2020). The detection of both CD69<sup>neg</sup> and CD69<sup>pos</sup> CD8 T cells in the PV is consistent with  
365 the enrichment of one cluster of CD69<sup>neg</sup> CD8 T cells from our initial CD45<sup>pos</sup> clustering (**Fig**  
366 **2**). CD8 and CD4 non-Treg cell subtypes were evenly distributed between all three layers (**Fig**  
367 **5D**). However, CD4 Tregs were enriched in the decidua compared to the PV (**Fig 5D**). The  
368 abundance and importance of Tregs throughout pregnancy in the decidua is well documented  
369 (Mjösberg et al., 2010; Salvany-Celades et al., 2019), but the role of Tregs in the CP and the PV  
370 is unclear, though we have shown PV Tregs function abnormally during intraamniotic  
371 inflammation (Toothaker et al., 2020). Moreover, there was an enrichment of CD4<sup>neg</sup> CD8<sup>neg</sup> that  
372 were also CD56<sup>neg</sup> and CD16<sup>neg</sup> double negative (DN) T cells in the PV (**Fig 5D, S5D**). These  
373 DN T cells were likely  $\gamma\delta$  T cells whose presence in the first trimester PV has been described  
374 (Bonney et al., 2000).

375 The detection of PV T cells expressing memory markers was recently reported in the  
376 third trimester rhesus macaque (Toothaker et al., 2020). However, their identification in human  
377 mid-gestation PV is novel. To investigate T cell signatures unique to the PV, we next compared  
378 the abundance of individual T cell clusters. While two clusters were enriched in the decidua (**Fig**  
379 **S5E**), cluster 9 CD4<sup>neg</sup> CD8<sup>neg</sup> T cells, cluster 4 CM CD8 T cells, and cluster 11 CD4 T cells  
380 were enriched in the PV (**Fig 5F**). Cluster 11 T cells were CCR4<sup>pos</sup> CXCR3<sup>neg</sup> CCR6<sup>neg</sup> (**Fig 5F,**  
381 **S5D**), surface marker expression pattern suggestive of a TH2 phenotype, however further  
382 analysis for detection of TH2 specific transcription factors (GATA3) is needed for confirmation.

383  
384 *Resting signatures define PV T cell subsets*

385 Since there was a resting, homeostatic trend in PV innate cells (**Fig 2**) and a  
386 resting/coinhibitory profile among PV APCs (**Fig 4**), we next explored if a resting phenotype was  
387 consistent among PV T cell subsets identified in **Fig 5D**. Among non-TRM T cells, PV T cell  
388 subsets exhibit reduced expression of CD69 (**Fig 5G**). Moreover, the PV housed fewer PD-1<sup>pos</sup>  
389 cells (**Fig 5H**) and reduced PD-1 per T cell compared to decidual counterparts (**Fig 5I-J**).  
390 Though PD-1 is a marker of T cell exhaustion, it is also upregulated upon activation of the T cell  
391 receptor (summarized in (Xu-Monette et al., 2017)). We propose this is the more likely role of  
392 observed down-regulation of PD-1 in PV T cells as it is consistent with the downregulation of  
393 CD69.

394




395  
396  
397  
398  
399  
400  
401  
402

**Figure 5. T cell subsets in placental tissues.** Representative images of T cells inside (top) and outside (bottom) fetal vasculature (CD31) in PV. (B) IMC images of T cell subtypes in PV. (C) Cumulative CyTOF tSNE for PV, CP and decidua CD45<sup>pos</sup> CD3<sup>neg</sup> HLA-DR<sup>pos</sup> cells. (D) Stacked bar graph of abundance of major immune subtype. (E) Relative expression of memory T cell markers in PV cell populations from (C). (F) Density plot separated by tissue of origin (C). Statistically significantly abundant clusters in PV outlined. Cumulative data of PV abundant clusters outlined in density plots. (G) MMI of CD69 from 2D gating of populations. (H) Abundance of PD-1<sup>pos</sup> T cells by 2-D gating. (I) PD-1 MMI from 2D gated



403 subsets. (J) Representative image of PD-1 on T cells in PV and decidua. \* = p value <0.05 upon post hoc  
404 analysis after Kruskal-Wallis (K-W) test. MMI = mean metal intensity. CM = central memory, EM = effector  
405 memory, TRM = tissue-resident memory.  
406



407  
408  
409  
410

**Figure S6.** (A) Splits from IF detection of T cells and PV endothelium. (B) Splits from representative IMC images of T cell subsets. T cells show in main figures identified in regions highlighted with white rectangles. (C) Pregating strategy for T cell population. (D) Clustergrammer heatmap used for cluster

411 identification (left) of tsne clusters mapped (right). (E) Cumulative data on abundance of decidua and CP  
412 enriched clusters. \* = p value < 0.05 after posthoc analysis from Kruskal-Wallis (K-W) test.


413

#### 414 *Maternal antigens can activate PV T cells*

415

416 To determine if PV T cells have a reduced activation profile due to functional  
417 abnormalities or immaturity, we scanned for the presence of activated T cells via the detection  
418 of HLA-DR, phosphorylated Histone H3, phosphorylated S6 and phosphorylated CREB in T  
419 cells using IMC. Based on the above markers we were able to identify both resting (**Fig 6A**) and  
420 activated T cells in the PV (**Fig 6B**). These results suggest that PV T cells are capable of being  
421 activated, consistent with our previous study in non-human primate which demonstrated TCR  
422 activation during *in utero* inflammation (Toothaker et al., 2020). As such we questioned if mid-  
423 gestation PV T cells could be activated in a TCR dependent manner. To test the functionality of  
424 the TCR pathway in PV T cells, we stimulated single cell suspensions from PV with soluble  
425  $\alpha$ CD3 and  $\alpha$ CD28 antibodies for 72 hours. Consistent with normal TCR pathway functionality,  
426 we observed increased CD69 expression after stimulation (**Fig 6C**) and an increased proportion  
427 of cells proliferating (**Fig 6D, S6B-C**) with stimulation. Validating our previous findings that PV T  
428 cells are fetal in origin and unique from the decidua and other fetal organs, we observed an  
429 increase in abundance of rapidly proliferating T cells identified by high Ki67 expression (Miller et  
430 al., 2018b) after 4 hours of stimulation with  $\alpha$ CD3 and  $\alpha$ CD28 antibodies in fetal T cells  
431 (placenta and intestine) compared to adult T cells (decidua and intestine) (**Fig 6E, S6D**). Of  
432 note, the placenta had the highest proportion of rapidly proliferating cells across all organs and  
433 ages following stimulation (**Fig 6**).


434 To discern what antigens could activate PV T cells, we stimulated isolated PV cells with  
435 either PMA/Ionomycin as a positive control or lysed cellular components from either: pregnancy-  
436 matched decidua, unmatched decidua or unmatched pooled donor PBMCs. Consistent with  
437 activation of PV T cells, we saw elevated CD69 expression in the PMA/Ionomycin, matched and  
438 unmatched decidual components conditions and but not with unmatched PBMC components  
439 (**Fig 6F**), suggesting that some antigens present in the decidua are capable of activating PV T  
440 cells. Validating the activation of PV T cells by decidual antigens, we also observed increased  
441 production of TNF $\alpha$  in a significant (though minor) proportion of CD69<sup>pos</sup> T cells (**Fig 6G, S6E-**  
442 **F**). These functional assays show that PV T cells have the potential to be activated by PV APCs  
443 through the TCR pathway and may become proinflammatory when stimulated in a TCR-  
444 dependent manner when exposed to particular antigens present in the uterine environment.



445  
446  
447  
448

**Figure 6. T cell activation in PV.** (A) IMC images of inactive T cell in PV. (B) IMC images of activated T cell in PV. (C) Representative flow plots (left) and quantification (right) of CD69<sup>pos</sup> T cell population. (D) Histogram showing proliferation as tracked by CFSE dye (left). Quantification of cells in proliferative

449 subsets identified. (E) Representative flow plots (top) and quantification (bottom) for proliferating (Ki67<sup>hi</sup>)  
 450 T cells after stimulation across tissues indicated. (F) Representative flow plots (left) and quantification  
 451 (right) of CD69<sup>pos</sup> T cell population. (F) Representative flow plots (left) and quantification (right) of TNF $\alpha$ <sup>pos</sup>  
 452 CD69<sup>pos</sup> T cell population. \* = p-value <0.05 in Mann-Whitney test.




453 **Figure S6.** (A) Splits from IMC images showing inactive and active T cells in PV. (B) Pregating strategy  
 454 for CD69<sup>pos</sup> and CFSE<sup>pos</sup> T cells. (C) Gating for proliferative populations quantified in main text. (D) Gating  
 455 for T cells in Ki67 proliferation experiment in main text. (E) Pregating strategy for CD69<sup>pos</sup> T cells used in  
 456 decidual stimulation. (F) Gating of TNF $\alpha$ <sup>pos</sup> population.

457  
 458  
 459 *Cytokine profile of PV T cells differentiates between mid-gestation, preterm, and term*  
 460 *pregnancies*

461 As we observed activation potential for mid-gestation PV T cells (**Fig 6**), we next  
462 explored if PV T cell activation was consistent across gestation and between healthy and  
463 complicated pregnancies. To assess T cell activation at baseline in the absence of any ex-vivo  
464 T cell activation as consequence to tissue digestion and cell isolation, we measured  
465 phosphorylated (p)ZAP70 expression with IHC. ZAP70 is phosphorylated following engagement  
466 of the TCR. Interestingly, we observed increased pZAP70 intensity per ZAP70<sup>pos</sup> stromal cell  
467 with increasing gestation (Term >preterm >mid-gestation) (**Fig 7A**). Building upon this  
468 observation that TCR activation is variable between groups, we next assessed T cell function  
469 following a 4-hour stimulation with  $\alpha$ CD3 and  $\alpha$ CD28 antibodies. In confirmation of our CyTOF  
470 findings (**Fig 6**), we report that the majority of PV T cells are CD8 T cells (**Fig S7A-C**). We  
471 observed activation of CD8<sup>pos</sup> T cells and very little activation of CD8<sup>neg</sup> T cells via CD69  
472 expression following stimulation in all three groups (**Fig 7B, S7A-B**). We therefore chose to  
473 analyze activated (CD69<sup>pos</sup>) CD8 T cells in subsequent analysis. Surprisingly, we found that the  
474 production of four cytokines, TNF $\alpha$ , IL-17A, GranzymeB (GRZB), IFN $\gamma$ , and did not vary  
475 between the three groups at baseline (**Fig 7C-F**). Interestingly, the potential for CD4 PV T cells  
476 to make GRZB has been reported in the non-human primate PV (Toothaker et al., 2020).  
477 Consistent with this finding we identified high production with of GRZB from CD8 CD69<sup>pos/neg</sup> T  
478 cells, CD8<sup>neg</sup> T cells and NK cells (**Fig S7D**). This finding Perhaps indicates an intrinsic function  
479 of PV T cells and NK cells as a second layer of antipathogen protection if the trophoblast layer  
480 is breached. In contrast to GRZB (**Fig 7E**) production of IL-17A, IFN $\gamma$ , and TNF $\alpha$  was observed  
481 by ~30-60% of CD69<sup>pos</sup> CD8 T cells (**Fig 7C-D,F**).


482 Although baseline production of cytokines was consistent between mid-gestation,  
483 preterm, and term PV T cells, alterations in cytokine production occurred following stimulation.  
484 Across all four cytokines PV T cells isolated four distinct term placentas responded consistently.  
485 In contrast, mid-gestation and preterm PV T cells had high patient-to-patient variability (**Fig 7G**).  
486 When tracking cytokine production of term PV T cells specifically, we observed no change in  
487 TNF $\alpha$  production. Additionally, we observed significant downregulation of IL-17A and GRZB  
488 following stimulation complimented with an increase in IFN $\gamma$  production (**Fig 7G**). To determine if  
489 the CD69<sup>pos</sup> CD8 T cells were downregulating GRZB in favor of IFN $\gamma$  we gated the two cytokines  
490 against one another (**Fig 7H**). Consistent with skewing of cytokine production from GRZB to  
491 IFN $\gamma$ , there was a significant decrease of GRZB single positive cells and a concurrent increase  
492 of IFN $\gamma$  single positive cells with stimulation (**Fig 7H**). No significant differences were observed  
493 in either double positive or double negative populations (**Fig S7E**). Importantly, this alteration  
494 from GRZB to IFN $\gamma$  production was specifically observed in CD69<sup>pos</sup> CD8 T cells and was not  
495 observed in other T cell subsets (**Fig S7F**). Collectively, this experiment revealed that CD69<sup>pos</sup>  
496 CD8 T cells in the PV are capable of producing a variety of cytokines at baseline and in full term  
497 healthy pregnancies a unique subset of CD69<sup>pos</sup> CD8 T cells skews its cytokine production to  
498 favor IFN $\gamma$  production upon stimulation of the TCR pathway.  
499



500  
501  
502  
503  
504  
505

**Figure 7. Gestational variation in PV T cell response.** (A) Representative images and quantification of pZAP70 expression via IHC. (B) Representative flow plots and quantification of CD69 expression in CD8<sup>pos</sup> and CD8<sup>neg</sup> T cells following stimulation. (C-F) Representative flow plots and quantification of TNF $\alpha$  (C), IL-17A (D), GranzymeB (GRZB) (E), and IFN $\gamma$  (F) at baseline. (G) Quantification of cytokine production before and after stimulation by CD69<sup>pos</sup> CD8<sup>pos</sup> T cells\* = p-value < 0.05 in Mann-Whitney test.

506 (H) Representative flow plots of GRZB and IFN $\gamma$  production by CD69<sup>pos</sup> CD8<sup>pos</sup> T cells\* = p-value <0.05 in  
 507 Mann-Whitney test.  
 508





509 **Figure S7.** (A) Pregating of flow cytometry to CD8 T cells. (B) Unstained control for CD69 and cytokine  
 510 stains in flow cytometry. (C) Quantification of CD8 T cell abundance in flow cytometry. (D) Quantification  
 511 of GRZB by T cell and NK subsets from flow cytometry. (E) Quantification of GRZB and IFN $\gamma$  populations  
 512 in CD8<sup>pos</sup> CD69<sup>pos</sup> T cells. (F) Quantification of GRZB and IFN $\gamma$  populations in T cell subsets.  
 513  
 514

515 In summation (**Fig 8**), we demonstrate that the intravillous compartment of the healthy  
 516 second trimester PV contains a diverse immune landscape comprised of innate cells such as  
 517 M $\phi$ s, NK cells and ILCs, as well as APCs including B cells, and memory T cells (**Fig 2**).  
 518 Moreover, we determined that the immune cells in the PV are likely capable of eliciting an  
 519 inflammatory response, but instead maintain immune homeostasis at baseline through a variety



520 of mechanisms. The mechanisms described include reducing chemotaxis by reduced  
521 expression of chemokine receptors on innate cells and low transcription of chemokine ligands in  
522 the PV overall (**Fig 3**). Moreover, PV APCs constitutively express PD-L1, possibly regulated by  
523 the high expression of IFN $\gamma$  by PV immune cells (**Fig 4**). This PD-L1 expression by APCs is  
524 potentially needed to prevent the activation of antigen-experienced PV T cells (**Fig 5**) which can  
525 be activated through the TCR pathway by antigens present in the uterine environment (**Fig 6**)  
526 and result in the secretion of a variety of cytokines (**Fig 7**).  
527



529 **Figure 8. Summary of major findings in study.** Image was generated with Biorender.com.

530

## 531 **Discussion**

532 Preserving tolerance at the fetal-maternal interface is critical for maintaining a healthy  
533 pregnancy. Studies of the roles of maternal immunity within the decidua and maternal peripheral  
534 blood have resulted in the discovery of important immunological tolerance mechanisms  
535 including: tolerogenic uterine NK cells (Erlebacher, 2013), unique populations of Tregs  
536 (Salvany-Celades et al., 2019) restriction of DC migration to the uterus (Tagliani and  
537 Erlebacher, 2011) and suppressive B cells (Huang et al., 2017). Until recently however, the  
538 contribution of leukocytes within the PV beyond Hofbauer cells (PV resident M $\phi$ s) has been far  
539 less explored.

540 Single cell studies within the past three years of the first trimester (Suryawanshi et al.,  
541 2018; Vento-Tormo et al., 2018) and full term (Pavličev et al., 2017; Pique-Regi et al., 2019)  
542 placenta highlighted the diversity of immune cells within the PV. Interestingly Pique-Rige and  
543 colleagues identified leukocyte signatures specific to the PV and highlighted a potential role for  
544 activated PV T cells in post-delivery PV (Pique-Regi et al., 2019). A finding also reported in  
545 preterm macaque PV (Toothaker et al., 2020). With these first and third trimester studies in  
546 mind, we hypothesized that the activated leukocytes detected by Pique-Regi (Pique-Regi et al.,  
547 2019) in humans and our group in non-human primates (Toothaker et al., 2020) may be present  
548 and poised to be activated in the PV earlier in gestation and subject to immunosuppressive  
549 mechanisms which maintain immune homeostasis within the PV in utero.

550 To answer these questions, we analyzed placental tissue (including decidua, PV and  
551 CP) and confirmed that there are diverse immune cells in second trimester PV samples that are  
552 located within the intravillous space and largely fetal in origin as suggested by the presence of  
553 the Y chromosome in majority of intravillous cells via FISH and the enrichment of Y genes in  
554 male fetuses. Although it is still possible that our analysis of PV immune cells included a  
555 proportion of maternal cells, ethical limitations precluded us from including maternal peripheral  
556 blood in our study. Future studies employing dual HLA-haplotyping/Y chromosome detection  
557 with staining for various immune populations on the same PV sections is needed to distinctly  
558 determine the fetal versus maternal origin of individual immune cell populations within the PV  
559 vasculature and stroma.

560 Previous studies have suggested that PV fetal immune cells are limited to Hofbauer cells  
561 (Thomas et al., 2021) However, the increased granularity provided by single cell methods, have  
562 allowed for the detection of T cells, B cells and NK cells of fetal origin in healthy term placentas  
563 (Pique-Regi et al., 2019). Moreover, a recent study identified infiltrating cells in the PV to be  
564 largely of fetal origin in cases of infectious villitis (Enninga et al., 2020) and Erbach et al.  
565 isolated T cells from single cell suspension at 18-24 weeks' gestation (Erbach et al., 1993). It is  
566 important to note that studies using single cell suspensions make the delineation of immune  
567 cells from the PV vasculature indistinguishable from those in the PV stroma. In the current  
568 study, by combining CyTOF to capture the diversity of PV immune cells and multiple imaging  
569 modalities, we identified a diverse immune landscape in the PV that was distinct from both the  
570 decidua and CP populations consisting of both innate and adaptive immune cells, including T  
571 cells, present outside the fetal vasculature in the intravillous space.

572 Focusing specifically on the innate non-APC population we identified NK cells, ILCs and  
573 M $\phi$ s to be present in the PV. Thomas et al. recently reported that Hofbauer cells in the first  
574 trimester are HLA-DR<sup>neg</sup> (Thomas et al., 2021), consistent with this we found an increased  
575 abundance of M $\phi$ s in the PV compared to the decidua in the innate HLA-DR<sup>neg</sup> compartment.  
576 Surprisingly, we report that many of these HLA-DR<sup>neg</sup> M $\phi$ s in the PV lacked the expression of  
577 CD163, a marker reported to be expressed in all Hofbauer cells (Reyes and Golos, 2018;  
578 Schliefssteiner et al., 2017). It is possible that CD163<sup>lo</sup> M $\phi$ s reflect downregulation of CD163 by

579 Hofbauer cells during cell isolation as has been reported in the presence of collagenase (Tang  
580 et al., 2011). However, it is also possible that Hofbauer cell populations are more diverse than  
581 previously thought and CD163 should be used in combination with other M $\phi$ s markers such as  
582 CD14, CD68 and DC-SIGN (Yang et al., 2017) in future studies. It is also possible that some of  
583 these cells represent non-Hofbauer macrophages within the PV.

584 In addition to reporting novel immune cell phenotypes, we identified mechanisms of  
585 immunosuppression and nonclassical function for multiple subsets of PV immune cells likely  
586 involved in preventing inflammation *in utero*. Specifically, we found that innate non-APCs  
587 expressed lower levels of multiple chemokine receptors including: CXCR3, CCR6, CCR4 and  
588 CCR7 than decidual counterparts. This finding is consistent with histologic evaluation of  
589 Hofbauer cells showing a lack of CCR7 and CX3CR1 staining (Joerink et al., 2011). This  
590 coupled with reduced expression of multiple chemokine ligands for these and other chemokine  
591 receptors we observed in the bulk RNAseq data, could suggest that innate cells in the PV are  
592 either more static or are mobile in a non-targeted manner at baseline.

593 We also report a diversity of HLA-DR<sup>pos</sup> cells present in the PV, where we identified  
594 mDCs, pDCs, B cells, M $\phi$ s and a population of HLA-DR<sup>pos</sup> NK cells. An antigen-presenting role  
595 for NK cells has been previously described (Roncarolo et al., 1991). The identification of fetal  
596 HLA-DR<sup>pos</sup> M $\phi$ s contrasts Thomas et al's recent findings showing no HLA-DR<sup>pos</sup> cells in the PV  
597 core up to the 10<sup>th</sup> week of gestation (Thomas et al., 2021). It should be noted that some of  
598 these HLA-DR<sup>pos</sup> M $\phi$ s in our study may reflect the presence of contaminate maternal M $\phi$ s  
599 (termed PAMMs) repairing breaks in the trophoblast layer. However, the location of HLA-DR<sup>pos</sup>  
600 cells in our study by both immunofluorescent and IMC show that some cells are located distant  
601 from the trophoblast layer and suggest that HLA-DR<sup>pos</sup> M $\phi$ s appear in the stroma after the time  
602 period studied by Thomas et al or between 10-18 weeks' gestation. It would be interesting to  
603 determine the fetal versus maternal origin of these second trimester HLA-DR<sup>pos</sup> M $\phi$ s and  
604 evaluate if the Hofbauer cell population from 18-23 weeks is transcriptionally distinct from those  
605 detected in prior studies (Vento-Tormo et al., 2018).

606 Similar to other innate population in the PV, we detected novel immunosuppressive  
607 mechanisms in APC subsets observed within the PV. Irrespective of PV APC ontogeny, we  
608 determined that PV APCs express more PD-L1 per cell than decidual counterparts. PD-L1's  
609 function as a coinhibitory molecule has been extensively studied (Sun et al., 2018). Moreover,  
610 PD-L1 expression can be mediated through interferon (IFN $\gamma$ ) signaling (Garcia-Diaz et al.,  
611 2017). Interestingly we showed that PV immune cells produce IFN $\gamma$  preferentially to TNF $\alpha$ ,  
612 another proinflammatory cytokine. These findings insinuate that PV APCs mediate in utero  
613 homeostasis by controlling T cell activation through the expression of coinhibitory ligands.  
614 Further validating the possibility of PV APC mediation of homeostasis via PD-L1 expression, we  
615 found that preterm PV have significantly reduced expression of PD-L1 on PV stromal cells  
616 compared to mid-gestation PV. Though it is not possible to determine if PD-L1 reduction  
617 precedes or is the consequence of preterm delivery, we concurrently observed increased  
618 pZAP70 in preterm PV over mid-gestation PV, consistent with increased T cell activation. Thus,  
619 it is possible that loss of PD-L1 on PV APCs results in elevated T cell activation leading to  
620 increased inflammation that is a well-documented phenotype in preterm deliveries (Romero et  
621 al., 2006). With the recent advancements in immunotherapy in multiple disease contexts it  
622 would be very interesting to study the local effects in the placenta and pregnancy outcomes of  
623 check-point blockade therapies throughout gestation.

624 The detection of memory T cells within the PV justifies the need for PV APCs to limit T  
625 cell activation. Memory T cells have been detected in multiple fetal human organs (Angelo et al.,  
626 2019; Halkias et al., 2019; Li et al., 2019; Schreurs et al., 2019; Stras et al., 2019b), and with in  
627 the non-human primate PV (Toothaker et al., 2020). Additionally activated and resting T cells  
628 have been detected in PV samples post-delivery (Pique-Regi et al., 2019) and central memory T

629 cell can be found in human cord blood from preterm infants (Frascoli et al., 2018). Here we  
630 report with both CyTOF and flow cytometry that PV T cells are enriched for CD8 and DN T cells,  
631 consistent with previous findings in term placentas (Erbach et al., 1993; Kim et al., 2008).  
632 Moreover, we found that at baseline PV T cells express low activation signatures (CD69 and  
633 PD-1) potentially suggesting that PV T cells have been previously educated (hence the memory  
634 marker expression) but remain quiescent due to either the lack of antigens or direct inhibition  
635 from PD-L1<sup>pos</sup> APCs. Moreover, we found no difference in baseline cytokine production by PV T  
636 cells between mid-gestation, preterm and term pregnancies, and increased proliferation of PV T  
637 cells compared to adult T cells in multiple organs further suggesting that PV T cell machinery  
638 and functionality is established early in pregnancy (prior to 17weeks' gestation). Interestingly,  
639 we observed high production of GRZB (>75%) among all T cell subsets and NK cells at baseline  
640 in term PV. GRZB production in CD4 and CD8 T cell subsets has been previously observed in  
641 non-human primate PV T cells in the third trimester, however its direct implications for placental  
642 health remain unclear (Toothaker et al., 2020). Interestingly, we observed downregulation of  
643 GRZB in CD69<sup>pos</sup> CD8 T cells and an increase in IFN $\gamma$  in these same cells upon stimulation of  
644 the TCR pathway. One explanation for this phenomenon could be that PV T cells have altered  
645 cytokine production between TCR-independent and TCR-dependent activation pathways. We  
646 propose that TCR-independent activation, such as by cytokines allows for consistent production  
647 of GRZB by CD69<sup>pos</sup> CD8 T cells at baseline. This TCR-independent high level of GRZB may  
648 allow PV T cells to act as a secondary layer of viral defense if the trophoblast layer is breached  
649 *in utero*; aide in the clearance of dying cells during cellular turnover as the placenta grows; or  
650 have a novel function specific to the placenta that remains to be elucidated. However, if PV T  
651 cells are activated through the TCR (experimentally measured with  $\alpha$ CD3/CD28 antibodies),  
652 they respond by changing cytokine production from a cytotoxic predominance to favor IFN $\gamma$   
653 production. It is also possible then that PV T cells increase IFN $\gamma$  upon TCR stimulation to  
654 increase PD-L1 on APCs to promote homeostasis and prevent *in utero* inflammation.  
655 Alternatively, IFN $\gamma$  production in activated PV T cells from term placentas participates in the  
656 induction of the labor cascade that would be consistent with data showing that both IFN $\gamma$  and  
657 TNF $\alpha$  from preterm cord blood memory T cells can induce uterine contractility (ref).

658 The presence of a placental and/or fetal microbiome as a source of potential antigens for  
659 PV T cells remains highly contested (Aagaard et al., 2014; de Goffau et al., 2019; Kuperman et  
660 al., 2020; Leiby et al., 2018; Mishra et al., 2021; Rackaityte et al., 2020; Theis et al., 2020).  
661 However, our group recently showed that xenobiotic metabolites including bacterial metabolites  
662 are present in the fetal intestine at 14 weeks' gestation (Li et al., 2020). As such, it is possible  
663 that maternal bacteria derived peptides similarly cross the placenta and educate fetal T cells.  
664 Fetal T cell activation by maternal antigens has also been implicated in preterm birth where T  
665 cells from cord exposed to maternal antigens delivered on cord blood APCs showed increased  
666 proliferation and secretion of TNF $\alpha$  and IFN $\gamma$  (Frascoli et al., 2018). As previously mentioned,  
667 our data indicates that T cells obtained from mid-gestation PV can be stimulated through the  
668 activation of the TCR signaling ( $\alpha$ CD3/CD28 antibodies) and when exposed to decidual  
669 antigens but not to unmatched PBMC antigens. Of note, we found many more T cells  
670 upregulating CD69 compared to those secreting TNF $\alpha$  upon decidual stimulation. It is likely that  
671 there is a differential response to maternal antigens among PV T cells. Further validating  
672 differential response to stimulation by mid-gestation PV T cells, we observed high patient to  
673 patient variability in cytokine secretion following stimulation. This was also observed in preterm  
674 PV T cells. Yet, term PV T cells behaved in an orchestrated fashion across all patients. This  
675 suggests that prior term PV T cells responses have not been fully established, but by the end of  
676 healthy pregnancy PV T cells mature enough to have similar responses upon activation. This  
677 variation in PV T cells responses to stimulation could be attributed to either incomplete T cell  
678 development or incomplete exposure to an array of antigens. This variability could alternatively

679 be attributed to PV T cells at term having a well-defined role whereas prior to complete  
680 gestation, the PV T cell response to stimulation is variable depending on the overall state of  
681 individual pregnancies. Collectively, these findings have identified unique functions of PV T cells  
682 and suggest that antigens could stimulate a proinflammatory PV T cell response upon crossing  
683 the placental barrier, however the multiple immunosuppressive mechanisms are in place as  
684 early as 17 weeks within the placenta to prevent inappropriate T cell activation including: limited  
685 chemotaxis of innate sensor cells and high expression of coinhibitory molecules by PV APCs.

686 Our study had several limitations of note the lack of genetic information to segregate  
687 fetal from maternal cells. It would be very interesting for a future cohort to definitively determine  
688 the origin of each PV immune cell subset identified in this work using dual *in situ* hybridization  
689 and immunodetection techniques. Furthermore, legal limitations prevented the collection of  
690 maternal and fetal blood to use for comparison.

691 The ability of fetal immune cells to execute mature functions has recently been validated  
692 in multiple cell types and organs throughout the fetus (Angelo et al., 2019; Frascoli et al., 2018;  
693 Halkias et al., 2019; McGovern et al., 2017; Schreurs et al., 2019; Stras et al., 2019a). As such  
694 the detection of immunosuppressive mechanisms to control this fetal immune response and  
695 prevent *in utero* inflammation is critical, particularly so at the point of contact and potential  
696 antigen exchange between mother and fetus. Throughout this study we have identified  
697 previously understudied immune cell populations within the mid-gestation placental villi.  
698 Moreover, we detected multiple mechanisms of immunosuppression utilized by these PV  
699 immune cells to help maintain homeostasis and prevent inflammation *in utero*. This work has  
700 implications for future studies to better understand the complex roles of fetal and maternal  
701 immune cells within the placenta and potentially contribute to a better understanding of immune  
702 tolerance in multiple disease contexts.

703

## 704 **Methods**

705

### 706 **Placental Tissue Collection**

707 Human products of conception were obtained through the University of Pittsburgh Biospecimen  
708 core after IRB approval (IRB# PRO18010491). Preterm placentas resultant from a variety of  
709 obstetric complications were obtained from the University of Pittsburgh MOMI Biobank. Term  
710 placentas were collected both at the University of Pittsburgh through the MOMI biobank and  
711 through the Yale University YURS Biobank from C-section deliveries devoid of obstetric  
712 complications (**Table 1**). Placental villi were separated using forceps under a light dissection  
713 microscope (Fisherbrand #420430PHF10) from the chorionic and amniotic membranes lining  
714 the chorionic plate (CP) and from the decidua basalis (referred to as decidua throughout  
715 manuscript) on the basal plate side of the placenta. Tissue was thoroughly washed with sterile  
716 PBS prior to cryopreservation and subsequent single cell isolation as previously described  
717 (Konnikova et al., 2018).

718

719 **RNA sequencing:** Snap frozen placental tissues were shipped on dry ice to MedGenome for  
720 mRNA extraction and library preparation. RNA extractions were completed with the Qiagen All  
721 Prep Kit (#80204). cDNA synthesis was prepped with the Takara SMART-seq kit (#634894) and  
722 NexteraXT (FC-131-1024, Illumina) was used to fragment and add sequencing adaptors. Quality  
723 control was completed by MedGenome via Qubit Fluorometric Quantitation and TapeStation  
724 BioAnalyzer. Libraries were sequenced on the NovaSeq6000 for Paired End 150 base pairs for  
725 90 million reads per sample.

726

727 **RNA sequencing analysis:** FASTQ files were imported and subsequently analyzed with CLC  
728 Genomics Workbench 20.0 (<https://digitalinsights.qiagen.com>). Briefly, paired reads were first  
729 trimmed with a quality limit of 0.05, ambiguous limit of 2 with automated read through adapter

730 trimming from the 3'-end with a maximum length of 150. Trimmed reads were then mapped to  
731 the homo\_sapiens\_sequence\_hg38 reference sequence. Differential gene expression was  
732 computed in CLC Genomics with an Across groups ANOVA-like comparison. Significantly  
733 differentially expressed genes were delineated as those with a p-value <0.05, False-Discovery  
734 Rate <20% and fold-change > absolute value of 2. Heatmaps for gene expression were created  
735 with Morpheus (<https://software.broadinstitute.org/morpheus>).

736  
737 **RISH:** Formalin fixed samples were sectioned and embedded in paraffin by the Pitt  
738 Biospecimen Core. Staining was completed per manufacturer's instructions for RNAScope®  
739 multiplex V2 detection kit (ACD Bio) coupled with immunofluorescent protein staining for either  
740 Cytokeratin19 (ab52625 Abcam) at 1:250 dilution. Echo® Revolve microscope at 20x was used  
741 to image sections. All images were batch processed using FIJI (Schindelin et al., 2012), and all  
742 edits were made to every pixel in an image identically across all patients per experiment.  
743 Quantification of cell populations was done using a custom pipeline in CellProfiler (McQuin et  
744 al., 2018).

745  
746 **FISH:** In situ hybridization for the Y chromosome was adapted from the protocol outlined  
747 in(Enninga et al., 2020). Briefly, slides were deparaffinized with a series of xylene and ethanol  
748 washes. Target retrieval was done at 95°C for 10 minutes, slides were placed in 70% ethanol,  
749 85% ethanol and 100% ethanol for 2 minutes each. DYZ3 probe (D5J10-034, Abbott  
750 Laboratories) was diluted 1:10 in LSI/WCP hybridization buffer (D6J67-011, Abbott  
751 Laboratories) and incubated for 5 minutes at 83°C prior to overnight hybridization at 37°C. Slides  
752 were soaked in SSC/0.1% NP-40 (ab142227, Abcam) to remove cover slips and placed in 2X  
753 SSC/0.1% NP-40 for 2 minutes at 74°C before mounting with antifade plus Propidium Iodide  
754 (p36935, Invitrogen). Slides were imaged on the LSM 710 (Leica Biosystems) confocal at the  
755 Yale Center for Cellular and Molecular Imaging.

756  
757 **RNA extraction and qPCR:** RNA was extracted from snap-frozen villi samples using the  
758 RNAEasy Minikit (#217004, Qiagen) RNA was converted to cDNA using iScript (#1708891,  
759 BioRad) reagents according to manufacturer protocol. Samples were run on the Taqman  
760 StepOnePlus Real-Time PCR System (Applied Biosciences) machine with probes for ACTB  
761 (Hs01060665\_g1) as housekeeping gene and with either XIST (Hs01079824\_m1) or EIF3AY  
762 (Hs01040047) all from Qiagen. Values undeterminable were given cycle values of 40 for  
763 quantification purposes.

764  
765 **Immunofluorescent staining:** Slides with 10um sections of FFPE tissue were deparaffinized  
766 with a series of xylene and ethanol washes. Antigen retrieval was performed in the Biocare  
767 Medical LLC decloaking chamber (NC0436641) for 1 hour with citrate-based antigen retrieval  
768 buffer (H-3300, Vector Laboratories) and washed with PBS. Slides were then blocked for 30  
769 minutes with 10% horse serum prior to overnight incubation at 4°C with primary antibodies.  
770 Slides were washed with PBS and incubated with secondary antibodies for 45 minutes at RT.  
771 Slides were mounted with Antifade mounting media + DAPI (H-1300, Vectashield).

772  
773 **Imaging mass cytometry:** Slides with 4um sections of FFPE tissue were deparaffinized with a  
774 series of xylene and ethanol washes. Antigen retrieval was performed at 95°C for 20 minutes  
775 using 1X Antigen Retrieval Buffer (#CTS013 R&D) and washed with water and dPBS. Slides  
776 were then blocked for 30 minutes with 3% BSA in dPBS prior to overnight incubation at 4°C with  
777 a primary antibody cocktail (**Table S8**). Slides were rinsed and co-stained with 191/193 DNA-  
778 intercalator (Fluidigm), rinsed and air dried for >20 minutes prior to analysis. Slides were  
779 analyzed on the Hyperion Mass Cytometer with an ablation energy of 4 and frequency of 100Hz

780 for ~30 minutes per section. Representative images were generated using Histocat++  
781 software(Catena et al., 2018).

782  
783 **CyTOF staining:** Samples were stained with antibody cocktail (**Table S4**) per previously  
784 published protocol(Stras et al., 2019a) and incubated with <sup>191</sup>Ir/<sup>193</sup>Ir DNA intercalator  
785 (Fluidigm) and shipped overnight to the Longwood Medical Area CyTOF Core. Data was  
786 normalized and exported as FCS files, downloaded and uploaded to Premium Cytobank®  
787 platform. Any files with insufficient cell number were excluded from analysis (**Table S5**). Gating  
788 and analysis was completed with cytofit(Chen et al., 2016) as published (Stras et al., 2019a).  
789 Cluster abundance was extracted, and statistically analyzed using R.

790  
791 **Stimulation of PV T cells:  $\alpha$ CD3/ $\alpha$ CD28 with CFSE:** Cells were isolated from cryopreserved  
792 PV samples as described throughout manuscript. Dead cells were removed prior to stimulation  
793 using Millitenyl dead cell removal kit (130-090-101 Millitenyl Biotec). Cells were incubated with  
794 CFSE (65-0850-85) alone or with  $\alpha$ CD3 (clone HIT3a, #300302, Biolegend) and  $\alpha$ CD28 (clone  
795 CD28.2, 302902, Biolegend) soluble antibodies for 72 hours rotating at 37°C + 5% CO<sub>2</sub>.  
796 GolgiPlug (51-2301K2, BD Biosciences) and GolgiStop (51-2092K2, BD Biosciences) were  
797 added for the last 4 hours of stimulation.  **$\alpha$ CD3/ $\alpha$ CD28 with Ki67:** Cells were isolated as  
798 described above and incubated with aforementioned  $\alpha$ CD3 and  $\alpha$ CD28 antibodies for 4 hours  
799 rotating at 37°C + 5% CO<sub>2</sub>.

800  
801 **Stimulation of PV T cells lysed decidual cells:** Single cells from PV and decidua were  
802 isolated from cryopreserved tissue as previously described(Konnikova et al., 2018). PBMCs  
803 were thawed and DMSO was washed out. PV tissue was thawed and made into single-cell  
804 suspensions (as described above). Cells were incubated in 5mLs of media with GolgiPlug (51-  
805 2301K2, BD Biosciences) and GolgiStop (51-2092K2, BD Biosciences) and designated stimuli.  
806 For PMA condition, PMA (1:2000) (Sigma-Aldrich) and Ionomycin (1:1000) (Sigma-Aldrich) were  
807 added. Decidua and PBMC cells were lysed via ultracentrifugation at max speed for 7 minutes  
808 and 1mL of lysed components was added to appropriate conditions. PV cells were exposed to  
809 stimuli for 4 hours at 37°C with 5% CO<sub>2</sub>.

810  
811 **Flow cytometry:** Post stimulation cells were washed with PBS and incubated with either  
812 Propidium Iodide or Zombie Aqua live/dead stain. Viability marker was washed out and cells  
813 were resuspended and spun down in FACS buffer then incubated with Human TruStain FcX  
814 (Biolegend) for 10 minutes prior to the addition of a surface antibody cocktail (**Table S9**) Cells  
815 were washed with FACS buffer and permeabilized with FoxP3 fix/perm (Invitrogen) overnight.  
816 Cells were washed with 1X FoxP3 Wash Buffer (Invitrogen) and incubated with intracellular  
817 antibodies. Cells were washed, fixed for 10 minutes with 4% PFA and resuspended in FACS  
818 buffer. All samples were run either on BD LSRFortessa  
819 (BDBiosciences) at the University of Pittsburgh Department of Pediatrics Flow Cytometry core  
820 (decidual cell stimulation) or on BD LSRII (BDBiosciences) at the Yale University Flow  
821 Cytometry core (all other stimulations). Output FCS files were analyzed with FlowJo ®.

822  
823  
824 **Statistics:** R version 3.6.1 with Kruskal-Wallis analysis and Dunn's multiple comparison test for  
825 post-hoc analysis among groups. One-tailed t-test was used to compare groups of two.  
826 Comparisons of mean expression values corrected using the Bonferroni method. P-values of  
827 0.05 or less were significant.

828



829 **Plot generation:** Plots comparing multiple groups were generated using Prism GraphPad 8. In  
830 each plot, each data point represents one subject as per figure description.

831  
832 **Data and code availability:** Data analyzed in this study has been stored according to IRB  
833 guidelines and is subject to institutional regulations. Requests can be directed to Lead Contact,  
834 Liza Konnikova [liza.konnikova@yale.edu](mailto:liza.konnikova@yale.edu).

835  
836 **Acknowledgements:** This project used the UPMC Hillman Cancer Center and Tissue and  
837 Research Pathology/Pitt Biospecimen Core shared resource which is supported in part by  
838 award P30CA047904. This research was supported in part by the University of Pittsburgh  
839 Center for Research Computing through the resources provided. We thank Yale Flow Cytometry  
840 for their assistance with LSRII service. The Core is supported in part by an NCI Cancer Center  
841 Support Grant # NIH P30 CA016359. We also thank Ansen Burr and the Hand Lab at The  
842 University of Pittsburgh for their help with RNA-sequencing analysis and Meghan Mooring and  
843 Dean Yimlamai for help with confocal microscopy and Biorender images.

844  
845 **Author Contributions:** JMT and LK conceived the work. CyTOF and flow cytometry  
846 procedures and analysis and drafting of manuscript were done by JMT supervised by LK.  
847 Tissue collection and preparation was done by JMT, RMC, CCM and OOO. IMC analysis was  
848 done by OOO. Immunocytochemistry was completed by BTM; RISH was done by RMC; RNA  
849 extraction/qPCR was performed by CCM. Cytometry bioinformatics consultation was done with  
850 PL supervised by GT. RNA sequencing assistance provided by DY. Figure construction was  
851 done by JMT and BTM. All authors contributed to the editing and compilation of the manuscript.

852  
853 **Declaration of Interests:** The authors have declared that no conflict of interest exists.

854  
855 **Supplemental Tables included at end of document**

856 Table S1. Patient Cohort  
857 Table S2. Differentially Expressed Genes Between Decidua, CP and PV  
858 Table S3. Selected Immune Genes  
859 Table S4. CyTOF Panel  
860 Table S5. Files Omitted from CyTOF Analyses  
861 Table S6. Cell Type Identification  
862 Table S7. IMC Panel  
863 Table S8. Differentially Expressed Chemokines  
864 Table S9. Flow Cytometry Antibodies

865  
866  
867 **References**

868  
869 Aagaard, K., Ma, J., Antony, K.M., Ganu, R., Petrosino, J., and Versalovic, J. (2014). The  
870 placenta harbors a unique microbiome. *Sci. Transl. Med.* *6*, 237ra65.  
871 Aghaepour, N., Ganio, E.A., Mcilwain, D., Tsai, A.S., Tingle, M., Van Gassen, S., Gaudilliere,  
872 D.K., Baca, Q., McNeil, L., Okada, R., et al. (2017). An immune clock of human pregnancy. *Sci.*  
873 *Immunol.* *2*.  
874 Angelo, L.S., Bimler, L.H., Nikzad, R., Aviles-Padilla, K., and Paust, S. (2019). CXCR6+ NK  
875 cells in human fetal liver and spleen possess unique phenotypic and functional capabilities.  
876 *Front. Immunol.* *10*, 469.  
877 Bonney, E.A., Pudney, J., Anderson, D.J., and Hill, J.A. (2000). Gamma-delta T cells in

878 midgestation human placental villi. *Gynecol Obstet Invest* 50, 153–157.

879 Buggert, M., Vella, L.A., Nguyen, S., Wu, V.H., Chen, Z., Sekine, T., Perez-Potti, A., Maldini,  
880 C.R., Manne, S., Darko, S., et al. (2020). The Identity of Human Tissue-Emigrant CD8<sup>+</sup> T Cells.  
881 *Cell* 183, 1946–1961.e15.

882 Catena, R., Montuenga, L.M., and Bodenmiller, B. (2018). Ruthenium counterstaining for  
883 imaging mass cytometry. *J. Pathol.* 244, 479–484.

884 Chen, H., Lau, M.C., Wong, M.T., Newell, E.W., Poidinger, M., and Chen, J. (2016). Cytofkit:  
885 A bioconductor package for an integrated mass cytometry data analysis pipeline. *PLoS Comput.*  
886 *Biol.* 12, e1005112.

887 Cibrián, D., and Sánchez-Madrid, F. (2017). CD69: from activation marker to metabolic  
888 gatekeeper. *Eur. J. Immunol.* 47, 946–953.

889 Elahi, S., Ertelt, J.M., Kinder, J.M., Jiang, T.T., Zhang, X., Xin, L., Chaturvedi, V., Strong, B.S.,  
890 Qualls, J.E., Steinbrecher, K.A., et al. (2013). Immunosuppressive CD71<sup>+</sup> erythroid cells  
891 compromise neonatal host defence against infection. *Nature* 504, 158–162.

892 Enninga, E.A.L., Raber, P., Quinton, R.A., Ruano, R., Ikumi, N., Gray, C.M., Johnson, E.L.,  
893 Chakraborty, R., and Kerr, S.E. (2020). Maternal T Cells in the Human Placental Villi Support  
894 an Allograft Response during Noninfectious Villitis. *J. Immunol.* 204, 2931–2939.

895 Erbach, G.T., Semple, J.P., Milford, E., Goguen, J., Osathanondh, R., and Kurnick, J.T. (1993).  
896 Phenotypic characteristics of lymphocyte populations isolated from middle gestation human  
897 placenta. *J Reprod Immunol* 25, 1–13.

898 Erlebacher, A. (2013). Immunology of the maternal-fetal interface. *Annu. Rev. Immunol.* 31,  
899 387–411.

900 Frascoli, M., Coniglio, L., Witt, R., Jeanty, C., Fleck-Derderian, S., Myers, D.E., Lee, T.-H.,  
901 Keating, S., Busch, M.P., Norris, P.J., et al. (2018). Alloreactive fetal T cells promote uterine  
902 contractility in preterm labor via IFN- $\gamma$  and TNF- $\alpha$ . *Sci. Transl. Med.* 10.

903 Garcia-Diaz, A., Shin, D.S., Moreno, B.H., Saco, J., Escuin-Ordinas, H., Rodriguez, G.A.,  
904 Zaretsky, J.M., Sun, L., Hugo, W., Wang, X., et al. (2017). Interferon Receptor Signaling  
905 Pathways Regulating PD-L1 and PD-L2 Expression. *Cell Rep.* 19, 1189–1201.

906 Gaynor, L.M., and Colucci, F. (2017). Uterine natural killer cells: functional distinctions and  
907 influence on pregnancy in humans and mice. *Front. Immunol.* 8, 467.

908 de Goffau, M.C., Lager, S., Sovio, U., Gaccioli, F., Cook, E., Peacock, S.J., Parkhill, J.,  
909 Charnock-Jones, D.S., and Smith, G.C.S. (2019). Human placenta has no microbiome but can  
910 contain potential pathogens. *Nature* 572, 329–334.

911 Halkias, J., Rackaityte, E., Hillman, S.L., Aran, D., Mendoza, V.F., Marshall, L.R., MacKenzie,  
912 T.C., and Burt, T.D. (2019). CD161 contributes to prenatal immune suppression of IFN $\gamma$ -  
913 producing PLZF<sup>+</sup> T cells. *J. Clin. Invest.* 129, 3562–3577.

914 Huang, B., Faucette, A.N., Pawlitz, M.D., Pei, B., Goyert, J.W., Zhou, J.Z., El-Hage, N.G.,  
915 Deng, J., Lin, J., Yao, F., et al. (2017). Interleukin-33-induced expression of PIBF1 by decidual  
916 B cells protects against preterm labor. *Nat. Med.* 23, 128–135.

917 Jiang, X., and Wang, H. (2020). Macrophage subsets at the maternal-fetal interface. *Cell Mol*  
918 *Immunol* 17, 889–891.

919 Joerink, M., Rindsjö, E., van Riel, B., Alm, J., and Papadogiannakis, N. (2011). Placental  
920 macrophage (Hofbauer cell) polarization is independent of maternal allergen-sensitization and  
921 presence of chorioamnionitis. *Placenta* 32, 380–385.

922 Kim, J.S., Romero, R., Kim, M.R., Kim, Y.M., Friel, L., Espinoza, J., and Kim, C.J. (2008).  
923 Involvement of Hofbauer cells and maternal T cells in villitis of unknown aetiology.

924 Histopathology 52, 457–464.

925 King, A., Balendran, N., Wooding, P., Carter, N.P., and Loke, Y.W. (1991). CD3<sup>-</sup> Leukocytes  
926 Present in the Human Uterus During Early Placentation: Phenotypic and Morphologic  
927 Characterization of the CD56<sup>++</sup> Population. *Dev. Immunol.* 1, 169–190.

928 Konnikova, L., Boschetti, G., Rahman, A., Mitsialis, V., Lord, J., Richmond, C., Tomov, V.T.,  
929 Gordon, W., Jelinsky, S., Canavan, J., et al. (2018). High-dimensional immune phenotyping and  
930 transcriptional analyses reveal robust recovery of viable human immune and epithelial cells from  
931 frozen gastrointestinal tissue. *Mucosal Immunol.* 11, 1684–1693.

932 Koopman, L.A., Kopcow, H.D., Rybalov, B., Boyson, J.E., Orange, J.S., Schatz, F., Masch, R.,  
933 Lockwood, C.J., Schachter, A.D., Park, P.J., et al. (2003). Human decidual natural killer cells are  
934 a unique NK cell subset with immunomodulatory potential. *J. Exp. Med.* 198, 1201–1212.

935 Kumar, B.V., Ma, W., Miron, M., Granot, T., Guyer, R.S., Carpenter, D.J., Senda, T., Sun, X.,  
936 Ho, S.-H., Lerner, H., et al. (2017). Human Tissue-Resident Memory T Cells Are Defined by  
937 Core Transcriptional and Functional Signatures in Lymphoid and Mucosal Sites. *Cell Rep.* 20,  
938 2921–2934.

939 Kuperman, A.A., Zimmerman, A., Hamadia, S., Ziv, O., Gurevich, V., Fichtman, B., Gavert, N.,  
940 Straussman, R., Rechnitzer, H., Barzilay, M., et al. (2020). Deep microbial analysis of multiple  
941 placentas shows no evidence for a placental microbiome. *BJOG* 127, 159–169.

942 Leiby, J.S., McCormick, K., Sherrill-Mix, S., Clarke, E.L., Kessler, L.R., Taylor, L.J.,  
943 Hofstaedter, C.E., Roche, A.M., Mattei, L.M., Bittinger, K., et al. (2018). Lack of detection of a  
944 human placenta microbiome in samples from preterm and term deliveries. *Microbiome* 6, 196.

945 Li, N., van Unen, V., Abdelaal, T., Guo, N., Kasatskaya, S.A., Ladell, K., McLaren, J.E.,  
946 Egorov, E.S., Izraelson, M., Chuva de Sousa Lopes, S.M., et al. (2019). Memory CD4<sup>+</sup> T cells  
947 are generated in the human fetal intestine. *Nat. Immunol.* 20, 301–312.

948 Li, Y., Lopez, G.E., Vazquez, J., Sun, Y., Chavarria, M., Lindner, P.N., Fredrickson, S., Karst,  
949 N., and Stanic, A.K. (2018). Decidual-Placental Immune Landscape During Syngeneic Murine  
950 Pregnancy. *Front. Immunol.* 9, 2087.

951 Li, Y., Toothaker, J.M., Ben-Simon, S., Ozeri, L., Schweitzer, R., McCourt, B.T., McCourt,  
952 C.C., Werner, L., Snapper, S.B., Shouval, D.S., et al. (2020). In utero human intestine harbors  
953 unique metabolome, including bacterial metabolites. *JCI Insight*.

954 McGovern, N., Shin, A., Low, G., Low, D., Duan, K., Yao, L.J., Msallam, R., Low, I., Shadan,  
955 N.B., Sumatoh, H.R., et al. (2017). Human fetal dendritic cells promote prenatal T-cell immune  
956 suppression through arginase-2. *Nature* 546, 662–666.

957 McQuin, C., Goodman, A., Chernyshev, V., Kametsky, L., Cimini, B.A., Karhohs, K.W., Doan,  
958 M., Ding, L., Rafelski, S.M., Thirstrup, D., et al. (2018). CellProfiler 3.0: Next-generation image  
959 processing for biology. *PLoS Biol.* 16, e2005970.

960 Miller, D., Romero, R., Unkel, R., Xu, Y., Vellido-Ortega, F., Hassan, S.S., and Gomez-Lopez,  
961 N. (2018a). CD71<sup>+</sup> erythroid cells from neonates born to women with preterm labor regulate  
962 cytokine and cellular responses. *J. Leukoc. Biol.* 103, 761–775.

963 Miller, I., Min, M., Yang, C., Tian, C., Gookin, S., Carter, D., and Spencer, S.L. (2018b). Ki67 is  
964 a Graded Rather than a Binary Marker of Proliferation versus Quiescence. *Cell Rep.* 24, 1105–  
965 1112.e5.

966 Mishra, A., Lai, G.C., Yao, L.J., Aung, T.T., Shental, N., Rotter-Maskowitz, A., Shepherdson,  
967 E., Singh, G.S.N., Pai, R., Shanti, A., et al. (2021). Microbial exposure during early human  
968 development primes fetal immune cells. *Cell*.

969 Miyazaki, S., Tsuda, H., Sakai, M., Hori, S., Sasaki, Y., Futatani, T., Miyawaki, T., and Saito, S.

970 (2003). Predominance of Th2-promoting dendritic cells in early human pregnancy decidua. *J.*  
 971 *Leukoc. Biol.* *74*, 514–522.  
 972 Mjösberg, J., Berg, G., Jenmalm, M.C., and Ernerudh, J. (2010). FOXP3<sup>+</sup> regulatory T cells and  
 973 T helper 1, T helper 2, and T helper 17 cells in human early pregnancy decidua. *Biol. Reprod.*  
 974 *82*, 698–705.  
 975 Mold, J.E., Michaëlsson, J., Burt, T.D., Muench, M.O., Beckerman, K.P., Busch, M.P., Lee, T.-  
 976 H., Nixon, D.F., and McCune, J.M. (2008). Maternal alloantigens promote the development of  
 977 tolerogenic fetal regulatory T cells in utero. *Science* *322*, 1562–1565.  
 978 Odorizzi, P.M., Jagannathan, P., McIntyre, T.I., Budker, R., Prahl, M., Auma, A., Burt, T.D.,  
 979 Nankya, F., Nalubega, M., Sikyomu, E., et al. (2018). In utero priming of highly functional  
 980 effector T cell responses to human malaria. *Sci. Transl. Med.* *10*.  
 981 Ohl, L., Mohaupt, M., Czeloth, N., Hintzen, G., Kiafard, Z., Zwirner, J., Blankenstein, T.,  
 982 Henning, G., and Förster, R. (2004). CCR7 governs skin dendritic cell migration under  
 983 inflammatory and steady-state conditions. *Immunity* *21*, 279–288.  
 984 Paloczi, K. (1999). Immunophenotypic and functional characterization of human umbilical cord  
 985 blood mononuclear cells. *Leukemia* *13 Suppl 1*, S87-9.  
 986 Pavličev, M., Wagner, G.P., Chavan, A.R., Owens, K., Maziarz, J., Dunn-Fletcher, C., Kallapur,  
 987 S.G., Muglia, L., and Jones, H. (2017). Single-cell transcriptomics of the human placenta:  
 988 inferring the cell communication network of the maternal-fetal interface. *Genome Res.* *27*, 349–  
 989 361.  
 990 Pique-Regi, R., Romero, R., Tarca, A.L., Sandler, E.D., Xu, Y., Garcia-Flores, V., Leng, Y.,  
 991 Luca, F., Hassan, S.S., and Gomez-Lopez, N. (2019). Single cell transcriptional signatures of the  
 992 human placenta in term and preterm parturition. *Elife* *8*.  
 993 PrabhuDas, M., Bonney, E., Caron, K., Dey, S., Erlebacher, A., Fazleabas, A., Fisher, S., Golos,  
 994 T., Matzuk, M., McCune, J.M., et al. (2015). Immune mechanisms at the maternal-fetal interface:  
 995 perspectives and challenges. *Nat. Immunol.* *16*, 328–334.  
 996 Rackaityte, E., Halkias, J., Fukui, E.M., Mendoza, V.F., Hayzelden, C., Crawford, E.D.,  
 997 Fujimura, K.E., Burt, T.D., and Lynch, S.V. (2020). Viable bacterial colonization is highly  
 998 limited in the human intestine in utero. *Nat. Med.* *26*, 599–607.  
 999 Reyes, L., and Golos, T.G. (2018). Hofbauer cells: their role in healthy and complicated  
 1000 pregnancy. *Front. Immunol.* *9*, 2628.  
 1001 Romero, R., Espinoza, J., Gonçalves, L.F., Kusanovic, J.P., Friel, L.A., and Nien, J.K. (2006).  
 1002 Inflammation in preterm and term labour and delivery. *Semin Fetal Neonatal Med* *11*, 317–326.  
 1003 Roncarolo, M.G., Bigler, M., Haanen, J.B., Yssel, H., Bacchetta, R., de Vries, J.E., and Spits, H.  
 1004 (1991). Natural killer cell clones can efficiently process and present protein antigens. *J.*  
 1005 *Immunol.* *147*, 781–787.  
 1006 Salvany-Celades, M., van der Zwan, A., Benner, M., Setrajcic-Dragos, V., Bougleux Gomes,  
 1007 H.A., Iyer, V., Norwitz, E.R., Strominger, J.L., and Tilburgs, T. (2019). Three Types of  
 1008 Functional Regulatory T Cells Control T Cell Responses at the Human Maternal-Fetal Interface.  
 1009 *Cell Rep.* *27*, 2537–2547.e5.  
 1010 Saso, A., and Kampmann, B. (2017). Vaccine responses in newborns. *Semin Immunopathol* *39*,  
 1011 627–642.  
 1012 Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch,  
 1013 S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012). Fiji: an open-source platform for  
 1014 biological-image analysis. *Nat. Methods* *9*, 676–682.  
 1015 Schliefssteiner, C., Peinhaupt, M., Kopp, S., Lögl, J., Lang-Olip, I., Hiden, U., Heinemann, A.,

1016 Desoye, G., and Wadsack, C. (2017). Human Placental Hofbauer Cells Maintain an Anti-  
1017 inflammatory M2 Phenotype despite the Presence of Gestational Diabetes Mellitus. *Front.*  
1018 *Immunol.* 8, 888.

1019 Schreurs, R.R.C.E., Baumdick, M.E., Sagebiel, A.F., Kaufmann, M., Mokry, M., Klarenbeek,  
1020 P.L., Schaltenberg, N., Steinert, F.L., van Rijn, J.M., Drewniak, A., et al. (2019). Human Fetal  
1021 TNF- $\alpha$ -Cytokine-Producing CD4<sup>+</sup> Effector Memory T Cells Promote Intestinal Development  
1022 and Mediate Inflammation Early in Life. *Immunity* 50, 462–476.e8.

1023 Shaw, T.N., Houston, S.A., Wemyss, K., Bridgeman, H.M., Barbera, T.A., Zangerle-Murray, T.,  
1024 Strangward, P., Ridley, A.J.L., Wang, P., Tamoutounour, S., et al. (2018). Tissue-resident  
1025 macrophages in the intestine are long lived and defined by Tim-4 and CD4 expression. *J. Exp.*  
1026 *Med.* 215, 1507–1518.

1027 Simonsen, K.A., Anderson-Berry, A.L., Delair, S.F., and Davies, H.D. (2014). Early-onset  
1028 neonatal sepsis. *Clin. Microbiol. Rev.* 27, 21–47.

1029 Stras, S.F., Werner, L., Toothaker, J.M., Olaloye, O.O., Oldham, A.L., McCourt, C.C., Lee,  
1030 Y.N., Rechavi, E., Shouval, D.S., and Konnikova, L. (2019a). Maturation of the human intestinal  
1031 immune system occurs early in fetal development. *Dev. Cell* 51, 357–373.e5.

1032 Stras, S.F., Warner, L., Toothaker, J.M., Olaloye, O.O., Oldham, A.L., McCourt, C.C., Lee,  
1033 Y.N., Rechavi, E., Shouval, D.S., and Konnikova, L. (2019b). Maturation of the Human  
1034 Intestinal Immune System Occures Early During Fetal Development. *Dev. Cell*.

1035 Sun, C., Mezzadra, R., and Schumacher, T.N. (2018). Regulation and Function of the PD-L1  
1036 Checkpoint. *Immunity* 48, 434–452.

1037 Suryawanshi, H., Morozov, P., Straus, A., Sahasrabudhe, N., Max, K.E.A., Garzia, A., Kustagi,  
1038 M., Tuschl, T., and Williams, Z. (2018). A single-cell survey of the human first-trimester  
1039 placenta and decidua. *Sci. Adv.* 4, eaau4788.

1040 Tagliani, E., and Erlebacher, A. (2011). Dendritic cell function at the maternal-fetal interface.  
1041 *Expert Rev Clin Immunol* 7, 593–602.

1042 Tang, Z., Tadesse, S., Norwitz, E., Mor, G., Abrahams, V.M., and Guller, S. (2011). Isolation of  
1043 hofbauer cells from human term placentas with high yield and purity. *Am J Reprod Immunol* 66,  
1044 336–348.

1045 Theis, K.R., Romero, R., Greenberg, J.M., Winters, A.D., Garcia-Flores, V., Motomura, K.,  
1046 Ahmad, M.M., Galaz, J., Arenas-Hernandez, M., and Gomez-Lopez, N. (2020). No consistent  
1047 evidence for microbiota in murine placental and fetal tissues. *MSphere* 5.

1048 Thomas, J.R., Appios, A., Zhao, X., Dutkiewicz, R., Donde, M., Lee, C.Y.C., Naidu, P., Lee, C.,  
1049 Cerveira, J., Liu, B., et al. (2021). Phenotypic and functional characterization of first-trimester  
1050 human placental macrophages, Hofbauer cells. *J. Exp. Med.* 218.

1051 Toothaker, J.M., Presicce, P., Cappelletti, M., Stras, S.F., McCourt, C.C., Chougnnet, C.A.,  
1052 Kallapur, S.G., and Konnikova, L. (2020). Immune Cells in the Placental Villi Contribute to  
1053 Intra-amniotic Inflammation. *Front. Immunol.* 11, 866.

1054 Vento-Tormo, R., Efremova, M., Botting, R.A., Turco, M.Y., Vento-Tormo, M., Meyer, K.B.,  
1055 Park, J.-E., Stephenson, E., Polański, K., Goncalves, A., et al. (2018). Single-cell reconstruction  
1056 of the early maternal-fetal interface in humans. *Nature* 563, 347–353.

1057 Xu-Monette, Z.Y., Zhang, M., Li, J., and Young, K.H. (2017). PD-1/PD-L1 Blockade: Have We  
1058 Found the Key to Unleash the Antitumor Immune Response? *Front. Immunol.* 8, 1597.

1059 Yang, S.W., Cho, E.H., Choi, S.Y., Lee, Y.K., Park, J.H., Kim, M.K., Park, J.Y., Choi, H.J., Lee,  
1060 J.I., Ko, H.M., et al. (2017). DC-SIGN expression in Hofbauer cells may play an important role  
1061 in immune tolerance in fetal chorionic villi during the development of preeclampsia. *J Reprod*

1062 Immunol 124, 30–37.  
1063 Zhang, X., Mozeleski, B., Lemoine, S., Dériaud, E., Lim, A., Zhivaki, D., Azria, E., Le Ray, C.,  
1064 Roguet, G., Launay, O., et al. (2014). CD4 T cells with effector memory phenotype and function  
1065 develop in the sterile environment of the fetus. *Sci. Transl. Med.* 6, 238ra72.  
1066  
1067